Macedonian Journal of Medical Sciences

www.degruyter.com uses cookies, tags, and tracking settings to store information that help give you the very best browsing experience.
To understand more about cookies, tags, and tracking, see our Privacy Statement
I accept all cookies for the De Gruyter Online site

Jump to ContentJump to Main Navigation
Open Access

Online

ISSN:
1857-5773

See all formats and pricing

Online
Open Access
*Prices in US$ apply to orders placed in the Americas only. Prices in GBP apply to orders placed in Great Britain only. Prices in € represent the retail prices valid in Germany (unless otherwise indicated). Prices are subject to change without notice. Prices do not include postage and handling. RRP: Recommended Retail Price.

Macedonian Journal of Medical Sciences

The Journal of ID Design 2012/DOOEL Skopje, Republic of Macedonia on behalf of the Macedonian Donor Registry (MKDR), Skopje, Republic of Macedonia


SCImago Journal Rank (SJR) 2014: 0.162
Source Normalized Impact per Paper (SNIP) 2014: 0.251
Impact per Publication (IPP) 2014: 0.259

DE GRUYTER OPEN

Open Access

Macedonian Journal of Medical Sciences (MJMS) publishes five types of full-length (15–30 double-spaced pages) manuscripts: (a) original research reports; (b) reviews and (c) abstracts from Master of Science thesis and PhD thesis, and (d) case reports. The journal also publishes two types of short (2–10 double-spaced pages) manuscripts: (e) brief communications, and (f) book reviews.

Aims and Scope

Why subscribe and read

Macedonian Journal of Medical Sciences (MJMS) publishes outstanding research articles in health and biological sciences.

Why submit 

Here are several ways in which you will benefit by publishing your paper in MJMS rather than another journal.

  • Wide dissemination. As an open access journal, articles in MJMS will always be freely available online, from our website and from PubMed Central, to anyone with internet access. This means that your work will have the broadest possible audience—the entire world. And recent studies have begun to suggest that open access articles get downloaded and cited more frequently.
  • Fast and professional peer review. MJMS is run by a team of experienced editors who have previously worked in medical publishing. The professional editors work closely with academic editors and peer reviewers to provide authors with an efficient, fair, and constructive review process.
  • Pre-submission inquiries. We are happy to look at abstracts or full papers prior to submission and will let you know within 48 hours whether we will consider the full paper.
  • Rapid publication. Because we are primarily an online journal, once a paper is accepted we do not have to wait for space to become available in the print journal before the paper is published. The time between acceptance and online publication is normally around 6 weeks, and can be expedited under special circumstances.
  • Print Journal. We are printing issues in the same time as they appeared online.
  • Author-friendly editing. We will not totally rewrite your paper to conform to house style. We will, of course, help authors whose first language is not English. In addition, we will not ask you to shorten your paper unnecessarily, although we do require papers to be written concisely.
  • No need to order reprints. Our open access license means that anyone can reprint and distribute our content, so long as they credit the author and cite the original source. Commercial publishing companies make huge profits reprinting your work—now you have an alternative.
  • Your research has the chance to have a high impact. MJMS continuously increase the quality of the content. Impact factors are only one measure of a journal's importance. There are a number of ways of measuring a journal's impact, including the influence it has on health policy, how widely read its papers are, and how frequently the papers are cited by other researchers.

Rejection Rate

  • About 40%

CrossCheck Plagiarism Screening System 

The Editors and Boards of Macedonian Journal of Medical Sciences are participating in a growing community of CrossCheck System's users in order to ensure that the content published is original and trustworthy. CrossCheck is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process (http://www.mjms.mk/MJMS_CrossCheck.htm).

ID Design 2012/DOOEL Skopje uses the iThenticate software to detect instances of overlapping and similar text in submitted manuscripts in all journals published by ID Design. Wherever you see the "CrossCheck Deposited" or "CrossCheck Depositor" logos, you can be reassured that the publisher whose content you are reading is committed to actively combating plagiarism and publishing original research. View ID Design 2012/DOOEL Skopje's plagiarism policy here. To find out more about CrossCheck visit http://www.crossref.org/crosscheck.html

DE GRUYTER OPEN
Language:
English
Type of Publication:
Journal

Instructions for Authors

Why Publish in Macedonian Journal of Medical Sciences (MJMS)?

Choosing where to send a paper is always a difficult decision. Here are several ways in which you will benefit by publishing your paper in MJMS rather than another journal.

  • Wide dissemination. As an open access journal, articles in MJMS will always be freely available online, from our website and from PubMed Central, to anyone with internet access. This means that your work will have the broadest possible audience—the entire world. And recent studies have begun to suggest that open access articles get downloaded and cited more frequently.
  • Fast and professional peer review. MJMS is run by a team of experienced editors who have previously worked in medical publishing. The professional editors work closely with academic editors and peer reviewers to provide authors with an efficient, fair, and constructive review process.
  • Pre-submission inquiries. We are happy to look at abstracts or full papers prior to submission and will let you know within 48 hours whether we will consider the full paper.
  • Rapid publication. Because we are primarily an online journal, once a paper is accepted we do not have to wait for space to become available in the print journal before the paper is published. The time between acceptance and online publication is normally around 6 weeks, and can be expedited under special circumstances.
  • Print Journal. We are printing issues in the same time as they appeared online.
  • Author-friendly editing. We will not totally rewrite your paper to conform to house style. We will, of course, help authors whose first language is not English. In addition, we will not ask you to shorten your paper unnecessarily, although we do require papers to be written concisely.
  • No need to order reprints. Our open access license means that anyone can reprint and distribute our content, so long as they credit the author and cite the original source. Commercial publishing companies make huge profits reprinting your work—now you have an alternative.
  • Your research has the chance to have a high impact. MJMS continuously increase the quality of the content. Impact factors are only one measure of a journal's importance. There are a number of ways of measuring a journal's impact, including the influence it has on health policy, how widely read its papers are, and how frequently the papers are cited by other researchers.

MJMS Editorial and Publishing Policies

  • Relationship to other Macedonian Medical Journals
    Macedonian Journal of Medical Sciences (MJMS) publish outstanding research articles in health and biological sciences. Several other medical journals (Makedon Med Pregl, God Zb Med Fak Skopje, Maked J Med, Prilozi, Acta Chir Maced, Acta Morphol, and Physioacta) are published in the Republic of Macedonia. Each journal has a team of professional and academic editors evaluating papers for publication. Occasionally, a manuscript is submitted that falls on the border between basic and clinical research or is classified as a professional paper. To ensure that such papers receive the fairest possible treatment, the professional editors of other medical journals may consult each other on relevant manuscripts. As a result, authors who have submitted their manuscript to MJMS may be encouraged instead to submit their paper to other medical journals (and vice versa). However, papers will never be transferred between the journals without an author's consent.
    Authors may request or editors may suggest that papers or presubmission enquiries (with reviews, if relevant) rejected from MJMS be forwarded to an appropriate other Macedonian medical journal, for further consideration. Editorial staff at MJMS will help with transferring papers.
  • Publication Charges
    To provide open access, MJMS use a business model in which our expenses—including those of peer review, journal production, and online hosting and archiving—are recovered in part by charging a subscription fee to the institutions or research sponsors. Editors and reviewers have no access to payment information, and hence inability to pay will not influence the decision to publish a paper. For further information, see our Subscriptions and Advertising.
  • Copyright and License Policies
    Upon submission of an article, authors are asked to indicate their agreement to abide by an open-access license. The license permits any user to download, print out, extract, archive, and distribute the article, so long as appropriate credit is given to the authors and source of the work. The license ensures that your article will be as widely available as possible and that your article can be included in any scientific archive.
    Upon publication, MJMS also intend to deposit all articles in PubMed Central. This complies with the policies of funding agencies, such as the NIH in the USA, the Wellcome Trust and the Research Councils in the UK, and the Deutsche Forschungsgemeinschaft in Germany, which request or require deposition of the published articles that they fund into publicly available databases. Please read about the Open Access License before submitting your paper.
  • Human and Animal Research
    All research involving humans and animals must have been approved by the authors’ institutional review board or equivalent committee, and that board must be named by the authors. In the case of human participants, informed consent must have been obtained, and all clinical investigation must have been conducted according to the principles expressed in the Declaration of Helsinki. Authors should submit a statement from the ethics committee or institutional review board indicating approval of the research. We also encourage authors to submit a sample of a patient consent form, and may require submission on particular occasions.
    For studies involving humans categorized by race/ethnicity, age, disease/disabilities, religion, sex/gender, sexual orientation, or other socially constructed groupings, authors should, as much as possible,
    • make explicit their methods of categorizing human populations; 
    • define categories in as much detail as the study protocol allows;
    • justify their choices of definitions and categories, including for example whether any rules of human categorization were required by their funding agency;
    • explain whether (and if so, how) they controlled for confounding variables such as socioeconomic status, nutrition, environmental exposures, etc.

In addition, outmoded terms and potentially stigmatizing labels should be changed to more current, acceptable terminology. Examples: "Caucasian" should be changed to "white" or "of `Western` European descent" (as appropriate); "cancer victims" should be changed to "patients with cancer".

  • Author Status
    MJMS follows the guidelines of the International Committee of Medical Journal Editors on authorship, and authors should make sure they are familiar with these guidelines. All authors will be contacted via e-mail at submission by the MJMS editorial office to indicate that they are aware of and approve the submission to MJMS of the manuscript, its content, authorship, and order of authorship. No decision can be made on an article until all authors have provided their assent to publication. The involvement of any professional medical writer in publication must be declared. We encourage authors to consult the European Medical Writers’ Association Guidelines on the role of medical writers.
  • Competing Interests
    Authors are asked at submission to declare whether they have any financial, personal, or professional interests that could be construed to have influenced their paper. Reviewers are also asked to declare any interests that might interfere with their objective assessment of a manuscript. Any relevant competing interests of authors must be available to editors and reviewers during the review process and will be stated in published articles. Click here for more general information on the MJMS’s policy regarding competing interests.
     
    Submission of Related Manuscripts
    When submitting an article, all authors are asked to indicate that they have not submitted a similar manuscript for publication elsewhere. If related work has been submitted elsewhere, then a copy must be included with the article submitted to MJMS. Reviewers will be asked to comment on the overlap between related submissions.
     
    Reviewer and Editor Exclusions
    Upon submission of a manuscript, authors are asked if they wish to include or exclude any specific academic editors or reviewers from the peer review of their article. The editorial team will respect these requests so long as this does not interfere with the objective and thorough assessment of the article. See the relevant guidelines for reviewers and more general information on MJMS’ policy regarding competing interests.
     
    Confidentiality
    Editors and reviewers are requested to treat all submitted manuscripts in strict confidence.
     
    Blogs, Wikis, Embargoes and the Media
    Authors are of course at liberty to present and discuss their findings ahead of publication: at medical or scientific conferences, on preprint servers, in public databases, and in blogs, wikis and other informal communication channels. We recommend, however, that authors not contact the media or respond to such contact unless an article has been accepted for publication and an embargo date has been established. Respect for press embargoes will help to ensure that your work is reported accurately in the popular media, and that the full peer-reviewed paper is freely available to any interested reader when the news item is published. If a journalist has covered a piece of work ahead of publication, this will not affect consideration of the work for publication.
     
    Scientific and Editorial Misconduct
    Scientific misconduct is defined by the Office of Research Integrity as "fabrication, falsification, plagiarism, or other practices that seriously deviate from those that are commonly accepted within the academic community for proposing, conducting, or reporting research." In cases where there is a suspicion or allegation of scientific misconduct or fraudulent research in manuscripts submitted for review, MJMS reserves the right to pass along these manuscripts to the sponsoring or funding institution or other appropriate authority for investigation. Although MJMS recognizes its responsibility to ensure that the suspicion of misconduct has been addressed, we do not ourselves make such determinations. MJMS is also represented at the Committee on Publication Ethics (COPE) and will abide by its principles and rulings.
     
    Corrections and Additions
    Corrections to articles will be considered for publication if the correction is judged by the editors to affect seriously the interpretation of the work and if all authors of the original publication have approved the correction. In cases of a dispute, authors should contact the editors. Authors should send corrections directly to the journal editorial staff.
     
  • Sharing of Materials, Methods, and Data
    Publication is conditional upon the agreement of authors to make freely available any materials and information associated with their publication that are reasonably requested by others for the purpose of academic, noncommercial research.

Data Availability

Open access applies to both the scientific literature and the data used to establish that literature. Publication is contingent on making data integral to a manuscript freely available without restriction, provided that appropriate attribution is given and that suitable mechanisms exist for sharing the data used in a manuscript and that in the case of clinical information patient confidentiality is not compromised.

  • Data for which public repositories have been established that are in general use should be deposited before publication, and the appropriate accession numbers or digital object identifiers published with the paper.
  • If an appropriate repository does not exist, data should be provided as supporting information with the published paper. If this is not practical, data should be made freely available upon reasonable request.
  • The conclusions of a study must not be dependent solely on the analysis of proprietary data. If proprietary data were used to reach a conclusion, and the authors are unwilling or unable to make these data public, then the paper must include an analysis of public data that validates the conclusions so that others can reproduce the analysis and build on the findings.

Note that any restrictions on the availability or on the use of datasets might be judged to diminish the significance of a paper and will therefore influence the decision about whether a paper should be published. These policies have been developed in accordance with the principles established in Sharing Publication-Related Data and Materials (National Academies Press, 2003).
 
Software/Algorithm Sharing

If new software or a new algorithm is central to a paper, the authors must provide sufficient information to allow interested users to reproduce and build on the authors’ work. In cases where the software/algorithm is not central to the paper, we nevertheless encourage authors to make all relevant materials freely available. Software can be provided under license where necessary, but any restrictions on the availability or on the use of materials might be judged to diminish the significance of a paper and therefore might influence the decision about whether a paper should be published subject to those conditions. These policies have been developed in accordance with the principles established in Sharing Publication-Related Data and Materials (National Academies Press, 2003).

  • Nomenclature
    The use of standardized nomenclature in all fields of science and medicine is an essential step toward the integration and linking of scientific information reported in published literature. We will enforce the use of correct and established nomenclature wherever possible:
    • We strongly encourage the use of SI units. If you do not use these exclusively, please provide the SI value in parentheses after each value.
    • Species names should be italicized (e.g., Homo sapiens) and the full genus and species must be written out in full, both in the title of the manuscript and at the first mention of an organism in a paper; after that, the first letter of the genus name, followed by the full species name may be used.
    • Genes, mutations, genotypes, and alleles should be indicated in italics. Use the recommended name by consulting the appropriate genetic nomenclature database, e.g., HUGO for human genes. It is sometimes advisable to indicate the synonyms for the gene the first time it appears in the text. Gene prefixes such as those used for oncogenes or cellular localization should be shown in roman: v-fes, c-MYC, etc.
    • The Recommended International Non-Proprietary Name (rINN) of drugs should be provided. 
  • Reporting Guidelines for Specific Study Designs
  • a. Clinical Trials
    We follow the WHO definition of a clinical trial. See http://www.who.int/ictrp/en/.
    "A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc"
    MJMS supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration. All trials initiated after 1 July 2005 must be registered prospectively in a publicly accessible registry (i.e., before patient recruitment has begun), or they will not be considered for publication. For trials initiated before 1 July 2005, all trials must be registered before submission to our journals. See the ICMJE faq on trial registration for further details. The WHO's list of approved registries is listed here.
    Authors of trials must adhere to the CONSORT reporting guidelines appropriate to their trial design. Please check the CONSORT statement web site for information on the appropriate guidelines for specific trial types. Before the paper can enter peer review authors must: 1) name in the paper trial registry, trial registration number, and IRB and 2) provide a copy of the trial protocol and a completed CONSORT checklist as supporting files (these documents will also be published alongside the paper, if accepted). The CONSORT flow diagram must be included as Figure 1. Any deviation from the trial protocol must be explained in the paper. Authors must explicitly discuss informed consent in their paper, and MJMS reserves the right to ask for a copy of the patient consent form. Information on statistical methods or participants beyond what is indicated in the CONSORT statement should be reported in the Methods section.
    MJMS supports the public disclosure of all clinical trial results, as mandated for example by the FDA Amendments Act, 2007. Prior disclosure of results on a public website such as clinicaltrials.gov will not affect the decision to peer review or acceptance of papers in MJMS.
  • b. Systematic Reviews and Meta-Analyses of Randomized Controlled Trials
    Reports of meta-analyses of randomized controlled studies should use the QUOROM statement as a guide (Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF `1999` Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement. Lancet354: 1896–900), and should include a copy of the QUOROM checklist.
  • c. Diagnostic Studies
    Reports of studies of diagnostic accuracy should conform to the STARD requirements.
  • d. Epidemiological Studies
    For reports of epidemiological studies, you should consult the STROBE initiative.
  • e. Microarray Experiments
    Reports of microarray experiments should conform to the MIAME guidelines, and the data from the experiments must be deposited in a publicly accessible database.

Publication of Studies Sponsored by Pharmaceutical Companies.
We support the development of guidelines for the reporting of studies sponsored by pharmaceutical companies.

Macedonian Journal of Medical Sciences is covered by the following services:

  • AGRICOLA (National Agricultural Library)
  • Baidu Scholar
  • Celdes
  • Chemical Abstracts Service (CAS)
  • CNKI Scholar (China National Knowledge Infrastructure)
  • CNPIEC
  • EBSCO (relevant databases)
  • EBSCO Discovery Service
  • Elsevier - EMBASE
  • Elsevier - SCOPUS
  • Genamics JournalSeek
  • Google Scholar
  • Index Copernicus
  • J-Gate
  • JournalTOCs
  • Meta (formerly Sciencescape)
  • Naviga (Softweco)
  • Primo Central (ExLibris)
  • ReadCube
  • ResearchGate
  • ScientificCommons
  • SCImago (SJR)
  • Socolar
  • Summon (Serials Solutions/ProQuest)
  • TDOne (TDNet)
  • Ulrich's Periodicals Directory/ulrichsweb
  • WorldCat (OCLC)

Editorial Office:
ID Design 2012/DOOEL Skopje
Naroden Front No. 13/45,
1000 Skopje, Republic of Macedonia.
Telephone: +389 389 23109851; +389 71 205072
e-mail: mjms@ukim.edu.mk
URL: http://www.mjms.mk/ | http://www.iddesign.mk/

Society or Institution:
Macedonian Donor Registry (MKDR)
Rajko Zhinzifov No. 48,
1000 Skopje, Republic of Macedonia
Telephone: +389 389 23109851; +389 70 255155
e-mail: mkdrmacedonia@yahoo.com
URL: http://www.mkdr.org.mk/

Editor-in-Chief
Mirko Spiroski, MD, PhD - FOUNDER AND EDITOR-IN-CHIEF. Founder and First Director of Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, 50 Divizia 16, 1109 Skopje, Republic of Macedonia. E-mail: mspiroski@mjms.mk

Doncho M. Donev, MD, PhD - EDITOR-IN-CHIEF FOR PUBLIC HEALTH.
Institute of Social Medicine, Medical Faculty, Ss Cyril and Methodius University of Skopje, 50 Divizija 16, 1109 Skopje, Republic of Macedonia. Tel.: +389 2 3298-580, Fax: +389 2 3298 582, Mobile: +389 70244760. dmdonev@mjms.mk

Deputy/ Managing Editors
Elizabeta Mukaetova-Ladinska, MD, MSc, PhD, MRCPsych - DEPUTY EDITOR-IN-CHIEF. Senior Lecturer/Honorary Consultant in Old Age Psychiatry, Newcastle University, Tyne and Wear, United Kingdom. E-mail: Elizabeta.Mukaetova-Ladinska@ncl.ac.uk

Marko Spasov, MD, PhD candidate - DEPUTY EDITOR-IN-CHIEF.
General Surgeon at University Clinic of Traumatology, Orthoapedics, Anesthesia, Reanimation, Intensive Care and Emergency Department; Medical Faculty, Skopje.
marspasov@mjms.mk

Sasho Stoleski, MD, MSc - DEPUTY EDITOR-IN-CHIEF.
Institute for Occupational Health of Republic of Macedonia - Skopje, WHO Collaborating Center, GA2LEN Collaborating Center, II Makedonska brigada 43, 1000 Skopje, Macedonia. Phone: +389 70 778 543, +389 71 314 435.
sstoleski@mjms.mk

Ivo Spiroski - MANUSCRIPT EDITION AND ELECTRONIC PUBLISHING.
Engineer of Design, ID Design 2012/DOOEL Skopje, Naroden Front 13/45, 1000 Skopje, Republic of Macedonia. http://www.iddesign.mk/ Tel.: +389 23109851; +389 71 205072.
ivospiroski@mjms.mk

Katarina Stavric, MD, PhD - EVIDENCE BASED MEDICINE. University Children Hospital, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Vodnjanska 17, 1109 Skopje, Republic of Macedonia. kstavric@hotmail.com

Editorial Board
Sonja Alabakovska, MD, PhD. Institute of Medical and Experimental Biochemistry, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, 50 Divizia 16, 1109 Skopje, Republic of Macedonia. E-mail: alabak@freemail.com.mk

Iva Ivanovska Ph.D. Harvard Medical School, Department of Genetics, 77 Avenue Louis Pasteur, NRB room 239, Boston, MA 02115 USA. Phone: +1 617-432-7557; fax: +1 617-432-6506. E-mail: ivanovska@genetics.med.harvard.edu

Jovan Jovanovski, PhD. Faculty of Physical Culture, University "Ss Kiril and Metodij", Skopje, Republic of Macedonia. E-mail: jovanovskijovan@yahoo.com

Petar Miloshevski, MD, PhD. Institute of Preclinical and Clinical Pharmacology with Toxicology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, 50 Divizia 16, 1109 Skopje, Republic of Macedonia. E-mail: pharma@on.net.mk

Elida Mitevska, MD, PhD. Institute of Histology and Embriology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, 50 Divizia 16, 1109 Skopje, Republic of Macedonia. E-mail: elida_mitevska@yahoo.com

Vesna Nikolova-Krstevski, PhD. Harvard Institutes of Medicine, HIM-201, 4 Blackfan Circle, Boston, MA, 02134, USA. Tel: 617-667-0728; Fax: 617-975-5299. E-mail: vnikolov@bidmc.harvard.edu

Nikola Panovski, MD, PhD. Institute of Microbiology and Parasitology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, 50 Divizia 16, 1109 Skopje, Republic of Macedonia. E-mail: n_panovski@yahoo.com

Iva Petkovska, MD. BIDMC - Beth Israel Deaconess Medical CenterRadiology W CC - 3 330 Brookline Ave. Boston, MA 02215, USA. Email: ipetkovs@bidmc.harvard.edu

Gorazd B. Rosoklija, MD, PhD. Professor at Columbia University and member of the Macedonian Academy of Sciences and Arts. E-mail: gbr2@columbia.edu

Aleksandar Sikole, MD, PhD, Professor of Medicine. University Clinic of Nephrology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia. E-mail: asikole@hotmail.com

Mirko Trajkovski, PhD. ETH Zürich, Wolfgang-Pauli-Str. 16/HPT D57, 8093 Zürich-CH. tel. +41 (0)44 633 3147; fax. +41 (0)44 633 1051. E-mail: trajkovski@imsb.biol.ethz.ch

Igor Tulevski, MD, PhD. Department of Cardiology, Academic Medical Center, Amsterdam, 1100 DD, T 020 707 2930; F 020 707 2931, The Netherlands. www.cardiokliniek.nl. E-mail: i.i.tulevski@amc.uva.nl; i.i.tulevski@cardiokliniek.nl

Zoran Zdravkovski, PhD. Faculty of Natural Sciences and Mathematics, Ss Cyril and Methodius University of Skopje, Skopje, Macedonia. E-mail: zoranzdr@gmail.com

Advisory Board
Nikola Angelov, DOS, MS, PhD. Pre-Doctoral Periodontics Clinic, Loma Linda University School of Dentistry, Department of Periodontics. Loma Linda, CA, 92350, USA. http://www.llu.edu/llu/faculty/directory/faculty.html?uid=nangelov; Tel: (909) 558-4643; Fax: (909) 558-7959. E-mail: nangelov@llu.edu

Aleksandar Dimovski, MD, PhD. Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia. E-mail: adimovski@ff.ukim.edu.mk

Ivo Donkov, MD, PhD. Staff Urologist, Lincoln County Hospital, UK. E-mail: idonkov@hotmail.com
Andrew J Dwork, MD, PhD. Department of Neuroscience, New York State Psychiatric Institute, Unit 62, 722 West 168th Street, New York, NY 10032, USA. Telephone 001 212 543 5563; fax 001 212 543 5769. E-mail: ajd6@columbia.edu

Dimitar Efremov, MD, PhD. Molecular Hematology, International Centre for Genetic Engineering and Biotechnology (ICGEB), Rome, Italy. E-mail: efremov@icgeb.org

Adriana Galan. Department of Health Programmes and Health Promotion, Institute of Public Health, Bucharest, Romania. E-mail: agalan@ispb.ro

Radka Kaneva, PhD. Department of Medical Chemistry and Biochemistry, Medical University - Sofia, Bulgaria. E-mail: kaneva64@yahoo.com; kaneva@medfac.acad.bg; kaneva@mmcbg.org

Branko Malenica, MD, PhD. Department of Immunology, Clinical Hospital Center Zagreb, Zagreb University School of Medicine, Zagreb, Croatia. E-mail: b_malenica@yahoo.com

Marija Mostarica-Stojkovic, MD, PhD. Institute of Microbiology and Immunology, University of Belgrade School of Medicine, Belgrade, Serbia. E-mail: mostarica@med.bg.ac.rs

Gianfranco Sinagra, MD, FESC. Department of Cardiology, "Ospedali Riuniti" and University of Trieste, Ospedale Cattinara - Strada di Fiume, 447, 34149 - Trieste, Italy. Tel.: +39 40 3994477. E-mail: gianfranco.sinagra@aots.sanita.fvg.it

Rumen Stefanov, MD, PhD. Information Centre for Rare Diseases and Orphan Drugs (ICRDOD), Bulgaria; Department of Social Medicine, Medical University of Plovdiv, Bulgaria. E-mail: stefanov@raredis.org

Milenko Tanasijevic, M.D., M.B.A. Director, Clinical Laboratories Division and Clinical Program Development, Pathology Department, Brigham and Women's Hospital, Dana Farber Cancer Institute, Associate Professor of Pathology, Harvard Medical School. Tel: 617-732-6360; Fax: 617-713-3056. E-mail: mtanasijevic@partners.org

Kiril Trpkov MD, FRCPC. Associate Professor, University of Calgary, Department of Pathology and Laboratory Medicine, Calgary Laboratory Services. 7007 14 st, Calgary SW, AB, Canada, T2V 1P9. Phone: (403) 943-3443; Fax: (403) 943-3333. E-mail: kiril.trpkov@cls.ab.ca

Publisher
DE GRUYTER OPEN
Bogumiła Zuga 32A Str.
01-811 Warsaw, Poland
T: +48 22 701 50 15

Please log in or register to comment.